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Drugs exert desired and undesired effects based on their binding interactions with protein target(s) and off-
target(s), providing evidence for drug efficacy and toxicity. Pioglitazone and rosiglitazone possess a common 
functional core, glitazone, which is considered a privileged scaffold upon which to build a drug selective for a 
given target—in this case, PPARγ. Herein, we report a retrospective analysis of two variants of the glitazone 
scaffold, pioglitazone and rosiglitazone, in an effort to identify off-target binding events in the rat heart to 
explain recently reported cardiovascular risk associated with these drugs. Our results suggest that glitazone has 
affinity for dehydrogenases, consistent with known binding preferences for related rhodanine cores. Both drugs 
bound ion channels and modulators, with implications in congestive heart failure, arrhythmia, and peripheral 
edema. Additional proteins involved in glucose homeostasis, synaptic transduction, and mitochondrial energy 
production were detected and potentially contribute to drug efficacy and cardiotoxicity. 
Introduction 
Type 2 diabetes drugs rosiglitazone and pioglitazone (Figure 1) are currently the only two thiazolidinedione-
based drugs on the market in the United States, and both share a common functional glitazone core. Although 
the Food and Drug Administration began restricting access to rosiglitazone in the United States in November of 
2011 because of increased risk of myocardial infarction, no such restrictions are in place for pioglitazone. An 
earlier thiazolidinedione-based drug, troglitazone, was removed from the market because of hepatotoxic 
effects,(1) but rosiglitazone and pioglitazone have not exhibited this effect, despite debate.(2, 3) Rosiglitazone 
and pioglitazone are stand-alone therapies for type 2 diabetes or for use in combination with metaformin or 
glimedpiride. Both drugs are thought to exert their therapeutic effect via binding to peroxisome proliferator-
activated receptor gamma (PPARγ) in adipose tissue,(4-7) leading to increased insulin sensitivity and better 
glycemic control. Despite their chemical and mechanistic similarities, there are large cohort studies suggesting 
that rosiglitazone causes peripheral edema(8, 9) and congestive heart failure(10-12) to a greater extent than 
pioglitazone. On the other hand, there are additional studies suggesting that there is no increased risk of 
peripheral edema(13) and adverse cardiovascular events(14, 15) between rosiglitazone in comparison to 
pioglitazone. 
 
Figure 1. Comparison of rosiglitazone and pioglitazone structures (A), showing the shared glitazone core 
(privileged scaffold) used to construct the affinity column for purification of proteins that bind the glitazone 
core. Under basic conditions, epoxide resin was reacted with the phenoxide of glitazone, and production of the 
glitazone-derivatized resin was confirmed using IR spectroscopy (data not shown). (B) Proteins were then eluted 
with either rosiglitazone or pioglitazone, and elution profiles, analyzed using tandem mass spectrometry, were 
compared. 
Serious concerns over cardiovascular events were first raised in 2007 as a result of a meta-analysis suggesting 
that rosiglitazone led to a 43% higher risk of myocardial infarction and a 64% higher risk of cardiovascular death 
when compared to patients receiving alternative type II diabetes treatments, not including 
pioglitazone.(10) Shortly after the 2007 meta-analysis was published, it was challenged because of its lack of 
heterogeneity, noting the exclusion of studies with zero events in treatment and control groups.(14, 16) A more 
recent and larger cohort study of 227 571 Medicare beneficiaries (average age of 74) identified a statistically 
significant 0.4% increased risk for stroke and heart failure as well as “all-cause mortality” for patients treated 
with rosiglitazone relative to pioglitazone.(11) However, a study in response to the Medicare beneficiaries study 
was published showing that there was no statistically significant difference between rosiglitazone and 
pioglitazone in “all-cause mortality” when 36 000 patients (average age of 54) were propensity score matched to 
control for variables such as age, gender, and previous history of cardiovascular problems.(15) Regardless, one 
argument is that rosiglitazone presents relatively higher cardiovascular risks, yet provides no additional 
therapeutic benefit, calling its utility of treating type 2 diabetes patients into question, while pioglitazone has 
not yet been reported to tip the benefit/risk balance. Questions as to how and if rosiglitazone may be leading to 
a relatively higher cardiovascular risk still remain largely unanswered. This discrepancy as to whether or not 
patients taking rosiglitazone run a higher risk of cardiovascular events and death than those taking pioglitazone 
and the underlying cause of the cardiovascular risks led to our exploration of the off-target binding profiles. 
In a previous study,(17) a chemical proteomic approach was presented for assessing target and anti-target (i.e., 
off-target) protein binding profiles for a rhodanine drug core. A similar approach is used herein to assess 
similarities and differences in the heart protein binding profiles between rosiglitazone and pioglitazone 
(Figure 1) but with more sophisticated selection techniques and computational/statistical analysis of binding 
profiles. As before, the common core or “privileged scaffold” (in this case glitazone) was used to create an 
affinity column (Figure 1) to which proteins from the target organ were bound. Rat heart tissue homogenate was 
used, since the goal was to identify protein binding events that may be associated with direct cardiovascular 
risk. Proteins were eluted with the glitazone-based drugs rosiglitazone or pioglitazone, and eluted proteins were 
identified using tandem mass spectrometry (MS). Similarities in binding patterns between these two elutions 
may suggest unknown mechanisms of action in addition to PPARγ binding, and possible sources of shared 
adverse effects. Conversely, differences may reveal direct protein complex binding events leading to the 
increased cardiovascular risk that may be unique to one drug or the other. 
In the current study, we have used this modified highly specific technique to make an unbiased comparison of 
similarities and differences between off-target molecular mechanisms that could lead to cardiotoxicity for the 
two major glitazone-based drugs rosiglitazone and pioglitazone. We used a two-phase selection method in 
which the protein must first bind to the privileged scaffold (i.e., glitazone) on the resin and then have higher 
affinity for the elution compound (i.e., rosiglitazone or pioglitazone). While our original hypothesis was that 
there would be significant off-target protein binding profile differences, thereby explaining an increase in 
rosiglitazone cardiotoxicity versus pioglitazone, as suggested by some meta-analyses,(10, 11) the data suggest 
that is not the case. Our results suggest that, while there is some differential protein binding, the off-target 
binding profiles are quite similar and the majority of proteins with potential for cardiotoxic effects did not 
exhibit significant differential binding in comparisons of the drugs, supporting conflicting meta-analyses stating 
that they contain a similar cardiotoxic risk.(15, 16) Binding profiles obtained for these drugs suggest that the 
cardiotoxic effects could be a result of disruption in ion channel modulation (for example, L-type calcium 
channel), neuronal signaling network in the heart, or heart energy demand regulation in diabetic patients taking 
both rosiglitazone and pioglitazone. This may implicate the drugs in similar mechanisms of action for adverse 
effect reactions due to off-target binding. In addition to PPARγ binding as a mechanism of action, additional 
sources of drug efficacy may occur from off-target binding, leading to increased insulin sensitivity. Notably, 
there are numerous proteins detected in rosiglitazone and pioglitazone elutions that regulate mitochondrial 
function, gluconeogenesis/glycolysis, and lipid metabolism. 
Results 
Assessing Specificity of Privilaged Scaffold Using Affinity Chromatography 
Glitazone was coupled to an epoxy resin to enable privileged scaffold-based (Figure 1) purification of target 
organ or tissue homogenate protein binding partners. The TZDs (thiazolidinediones) contained within the core 
glitazone scaffold contain the majority of binding interactions seen in crystal structures with PPARγ(4) and have 
affinity for the target, so while there is a distinct chance some proteins might be missed, the majority of 
interacting proteins and potential complex partners will be captured by the affinity resin. Differences seen in 
comparisons of rosiglitazone and pioglitazone elutions will identify proteins with selectivity for these additional 
drug functional components, added to the glitazone core. Reaction of the glitazone with an epoxy resin was 
confirmed through detection of new hydroxy peaks (−OH) in an infrared (IR) spectrum of the coupled resin (data 
not shown), due to opening of the epoxide ring (Figure 1). The IR spectrum indicated that glitazone was 
efficiently coupled; an additional phenol column was created using p-cresol and the epoxy resin (data not 
shown) for comparison. 
Previous literature indicated that a rhodanine group, related to the TZD core of glitazone, exhibits high affinity 
for dehydrogenase enzymes in general,(17) so it was utilized as a test group to examine drug specificity for heart 
homogenate proteins. Glitazone, rosiglitazone, and pioglitazone elutions all bound numerous dehydrogenase 
enzymes. Off of a glitazone scaffold, glitazone eluted 16 dehydrogenase enzymes, rosiglitazone eluted 6, and 
pioglitazone eluted 5 (Table 1), showing a higher degree of specificity obtained by the drugs compared to the 
core group. Suppression of dehydrogenases have also been shown to effect adipogenesis,(18, 19) a primary 
effect of the drugs. Eluted proteins with higher affinity for the drugs will have an increase in peptide/scan count 
compared to glitazone or vice versa when normalized for total scan count, helping determine which proteins 
demonstrate the highest affinity for the drugs. Additionally, proteins previously shown to be affected in 
processing and secretion after administration of TZDs, such as cytoplasmic superoxide dismutase (SODC) 
(Supporting Information Table 1), catalase (Suppprting Information Table 2), and numerous ion channels 
(Table 4), were found to interact with the drugs, in turn relating specificity further to previous literature.(18, 20-
26) 
Table 1. Dehydrogenase Enzymes with Affinity for the Thiazolidinedione in the Glitazone Scaffold 
    peps/scans   
accession no
. 
description glitazone rosiglitazone pioglitazone 
P15650 acyl-CoA dehydrogenase, long-chain specific, 
mitochondrial 
19/85 4/10 14/72 
P04636 malate dehydrogenase, mitochondrial 18/182 3/11 NDa 
P42123 l-lactate dehydrogenase B chain 16/57 7/15 11/32 
P10860 glutamate dehydrogenase 1, mitochondrial 15/28 ND ND 
P04797 glyceraldehyde 3-phosphate dehydrogenase 14/48 4/8 6/15 
Q60597 2-oxoglutarate dehydrogenase E1 component, 
mitochondrial 
14/27 ND 5/9 
P45953 acyl-CoA dehydrogenase, very-long-chain-
specific, mitochondrial 
13/23 ND ND 
P54071 isocitrate dehydrogenase [NADP], 
mitochondrial 
11/23 ND ND 
P08503 acyl-CoA dehydrogenase, medium-chain-
specific, mitochondrial 
10/18 ND ND 
P14152 malate dehydrogenase, cytoplasmic 9/23 6/17 ND 
O08749 dihydrolipoyl dehydrogenase, mitochondrial 8/19 9/37 10/69 
P15651 acyl-CoA dehydrogenase, short-chain-specific, 
mitochondrial 
6/9 ND ND 
P04642 l-lactate dehydrogenase A chain 7/19 ND ND 
P26284 pyruvate dehydrogenase E1 component α-
subunit, mitochondrial 
6/11 ND ND 
Q9D2G2 dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial 
4/12 ND ND 
Q9WVK7 short chain 3-hydroxyacyl-CoA dehydrogenase, 
mitochondrial 
3/12 ND ND 
aND = not detected. 
Because of the importance of achieving high specificity with this two-phase selection purification process, 
protein lists were validated further to show enrichment of lower abundance binding partners, expanding the 
dynamic range. This validation was completed by comparing nonspecific high salt elutions versus drug elutions 
of heart proteins, such as ion channels, off of the glitazone scaffold. For instance, the L-type calcium channel 
(CAC1F; rosiglitazone, p = 2.15 × 10–6; pioglitazone, p = 0.000 72), chloride channel protein 6 (CLCN-6; 
rosiglitazone, p = 0.000 15; pioglitazone, p = 3.21 × 10–7), and salt-incucible kinase 2 (SIK2; rosiglitazone, p = 4.68 
× 10–11; pioglitazone, p = 3.86 × 10–10) were all significantly increased in drug versus high salt elutions off the 
glitazone scaffold. This enhancement of the dynamic range of detection was consistently seen across the data 
set. An alternative validation was required for those highly abundant proteins that bound to glitazone and had 
high affinity for rosiglitazone or pioglitazone because high salt would elute these proteins in abundance off of 
the scaffold. Comparisons can be made between the phenol and glitazone scaffold drug elutions to validate this 
data set, since the glitazone should contain higher specificity for the proteins than general hydrophobic binding 
achieved on the phenol column. By use of ATP synthase β-chain as an example of the more abundant proteins 
present, there was significant enrichment by rosiglitazone (p = 0.031) and pioglitazone (p = 0.000 53) off the 
glitazone versus phenol scaffolds. 
Total Heart Protein Eluted off Glitazone and Phenol Columns 
Heart protein homogenates were bound to the glitazone column and eluted off using high salt Tris-buffered 
saline, pH 6.8 (nonspecific), 2 mM glitazone (same as scaffold), 50 μM rosiglitazone (selecting for highly specific 
binding), and 50 μM pioglitazone (selecting for highly specific binding) elutions. Eluted proteins were prepared 
for orbitrap tandem MS analysis and compared against the UniprotKB rodent database. During data analysis 
utilizing in-house Visualize software,(27) technical and biological replicates were combined and filtered for 
removal of common contaminants and redundant protein/peptide hits, a P ≥ 0.85 for the protein, and a scan 
count ≥8 for any given protein. Total protein elution sets consisted of proteins detected from all elution 
conditions combined for any given column and filtered as noted above, providing a more complete list of all 
proteins bound. In assessing total elution sets (i.e., all elution sets combined and filtered) for both the phenol 
(Figure 2A) and glitazone (Figure 2B) columns, there were 349 and 222 total heart proteins, respectively. Of the 
total protein elution data set, rosiglitazone displayed a significant increase in 65 proteins (5 unique) eluted off 
the glitazone column and 18 proteins (5 unique) eluted off the phenol column compared to the total. 
Pioglitazone displayed a significant increase in 37 proteins (1 unique) eluted off the glitazone column and 23 
proteins (7 unique) eluted off the phenol column. Only six proteins overlapped between those significantly 
increased with rosiglitazone on the two columns and three proteins for pioglitazone elutions, which displayed 
the increased specificity of the drugs for elution of proteins bound to the glitazone column. When overlapping 
proteins between different elution conditions in the total protein bound data set were accounted for, there 
were 156 proteins bound to the glitazone column and 122 proteins bound to the phenol column not significantly 
increased when compared to individual drug elution conditions against the total. 
 
Figure 2. Distribution of heart proteins eluted off a phenol or glitazone scaffold, which showed a significant 
increase (Sig. ↑; p ≤ 0.05) in abundance relative to total proteins eluted by all conditions (i.e., all detected 
proteins bound to the particular column). Elution conditions were compared in terms of the total number of 
proteins bound and then eluted from the affinity column. Total protein bound then eluted from the column is 
defined as proteins detected by tandem MS for all elution conditions combined and filtered. Numbers of 
proteins that showed a significant increase in levels after elutions using high salt TBS (nonspecific) (HS), glitazone 
(Glit), rosiglitazone (Rosi), and pioglitazone (Pio) off of the (A) phenol scaffold and (B) glitazone scaffold are 
indicated. 
Total protein bound comparisons included the most nonspecific elution condition, high salt TBS at pH 6.8, in 
which eluted proteins were dependent on a single selection for binding to the core compound (i.e., glitazone). 
However, glitazone containing compound elutions contain a second target specific selection process through 
addition of the compound in the elution. Comparing the nonspecific single selection with the double selection 
protein data sets can skew the numbers, so additional comparisons were generated (Figure 3). In order to focus 
on scaffold-bound proteins with the highest degree of specificity for the glitazone compounds, the strategy was 
enhanced by focusing on protein data sets compiled by adding a target specific elution by glitazone, 
rosiglitazone, and pioglitazone. A three-way comparison of the glitazone containing compound elution protein 
data sets (filtered as described for the total protein data sets) was generated (Figure 3). The phenol column 
resulted in 101 proteins and the glitazone column in 153 proteins eluting and passing the stringent filters. This 
type of analysis is unique because of the two-phase selection of affinity for the compound on the resin and then 
a second selection for the compound used for elution. Once again, the specificity among TZD compounds off a 
glitazone column compared to the phenol column can be observed by the increase in bound proteins eluted off 
by the specific drugs during the specific two-phase selection. 
 
Figure 3. Three-way comparison of proteins found in glitazone, rosiglitazone, and pioglitazone heart protein 
elutions off of affinity columns comprised of a phenol or glitazone scaffold. Each sphere represents a specific 
elution condition as indicated, and any overlap between spheres is proteins common to multiple conditions. (A) 
Comparisons of glitazone, rosiglitazone, and pioglitazone elutions from a phenol scaffold and (B) from a 
glitazone scaffold are indicated. 
Direct Comparison of Rosiglitazone versus Pioglitazone Elutions off a Glitazone Scaffold 
Proteins bound to the glitazone scaffold and eluted with the target-specific glitazone drug contain the highest 
degree of specificity and were the focus henceforth. During comparison analysis of rosiglitazone and 
pioglitazone elutions, proteins were filtered as before, along with addition of a run count of ≥6, and 
normalization for total scan count between groups provided an expected scan count.(27) Comparisons were 
then separated into five main categories: (1) unique to rosiglitazone elutions, (2) unique to pioglitazone elutions, 
(3) significantly increased in rosiglitazone elutions, (4) significantly increase in pioglitazone elutions, and (5) not 
significantly different between the drugs. In direct comparisons of the proteins eluted off the glitazone scaffold 
by rosiglitazone or pioglitazone, there were more similarities than differences. Many of the proteins that were 
significantly increased with rosiglitazone or pioglitzone in comparisons were still abundant in the elutions 
resulting from both drugs. Altogether, 92 heart proteins passed the appropriate filters for the comparison of 
rosiglitazone to pioglitazone (Supporting Information Table 1). Of the 92 proteins present in the direct protein 
binding comparison data set between rosiglitazone and pioglitazone, 67% (62 proteins) were not significantly 
different. Only 6.5% (6 proteins) were unique to rosiglitazone and 6.5% (6 proteins) unique to pioglitazone 
(Table 2). There were 11% (10 proteins) and 8.7% (8 proteins) significantly increased in rosiglitazone and 
pioglitazone elutions, respectively (Table 3). Since there were few unique differences between rosiglitazone and 
pioglitazone, we further assessed the data set by examining those heart proteins that were significantly 
increased in abundance (p ≤ 0.05) in elutions by one drug versus the other because those proteins are 
candidates to explain mechanistic differences that could result in impaired cardiac function. While rosiglitazone 
elutions contained 10 proteins that were significantly increased compared to pioglitazone, the fold change was 
much less drastic than the 8 proteins significantly increased by pioglitazone elution (Table 3). The proteins in 
Tables 2 and 3 only indicate slight differences in rosiglitazone versus pioglitazone elutions, and the proteins fall 
in similar mechanistic pathways compared to those not significantly different between the drugs, indicating they 
are potentially affecting the same biological processes. Altogether, both drugs contained off-target binding 
partners involved in ion transport modulation (Table 4) and neuronal networks (Table 5), which could have 
potential impact on heart muscle contraction. Additionally, proteins involved in the gluconeogenesis/glycolysis 
cycle, long-chain fatty acid uptake, transport between the mitochondria and cytoplasm, amino acid metabolism, 
and energy transduction were identified (Tables 1–5 and Supporting Information Table 1). 
Table 2. Heart Proteins Unique to Rosiglitazone or Pioglitazone Elution off a Glitazone Scaffold 
      scan count    
accession no. annotated protein peptides actual expected norm p 
Heart-Unique to Rosiglitazone      
P48744 norrin precursor 1 52 26.34 4.05 × 10–17 
P37285 kinesin light chain 1 1 28 14.18 6.73 × 10–10 
O08755 hepatocyte nuclear factor 6 1 18 9.12 7.47 × 10–7 
P14152 malate dehydrogenase, cytoplasmic 6 17 8.61 1.51 × 10–6 
Q9WVE8 protein kinase C and casein kinase substrate in neurons protein 2 1 14 7.09 1.27 × 10–5 
Q03147 cell division protein kinase 7 1 9 4.56 0.00047 
Heart-Unique to Pioglitazone      
P16617 phosphoglycerate kinase 1 10 22 10.86 2.49 × 10–8 
P00507 aspartate aminotransferase, mitochondrial precursor 6 20 9.87 1.07 × 10–7 
P43432 interleukin-12 β chain precursor 1 14 6.91 8.72 × 10–6 
Q923 × 8 trace amine-associated receptor 7b 1 13 6.42 1.83 × 10–5 
P07335 creatine kinase B-type 5 11 5.43 8.10 × 10–5 
P20059 hemopexin precursor 3 9 4.44 0.00036 
 
Table 3. Heart Proteins Present at Relatively Higher Levels after Elution from the Glitazone Scaffold-Based Column Using Rosiglitazone or Pioglitazone 
      scan count      
accession no. annotated protein peptides rosi/exp pio/exp fold 
change 
norm p 
Increased with Rosiglitazone vs 
Pioglitazone Elution 
      
P09321 chorionic somatomammotropin hormone 2 
precursor 
1 12/7.60 3/7.40 3.92 0.018 
Q8BQP8 Rab11 family interacting protein 4 2 15/9.62 4/9.38 3.74 0.011 
Q9QX72 SECIS-binding protein 2 1 44/29.37 14/28.63 3.22 8.12 × 10–5 
Q04690 neurofibromin 3 12/8.10 4/7.90 3.10 0.046 
Q8BGE5 Fanconi anemia group M protein homologue 3 17/11.65 6/11.35 2.94 0.023 
Q4FZZ1 PX domain-containing protein kinase-like 
protein 
1 23/16.21 9/15.79 2.64 0.014 
Q9QZM3 cardiotrophin-like cytokine factor 1 precursor 1 25/17.73 10/17.27 2.56 0.012 
Q9QUH6 Ras GTPase-activating protein SynGAP 2 62/46.09 29/44.91 2.12 0.00073 
Q9QZR6 septin-9 1 59/44.06 28/42.94 2.08 0.0012 
Q9QXY7 membrane transport protein XK 1 61/46.59 31/45.41 1.88 0.0024 
Increased with Pioglitazone vs 
Rosiglitazone 
      
P48500 triosephosphate isomerase 13 6/30.89 55/30.11 6.46 8.61 × 10–
12 
P00564 creatine kinase M-type 12 4/18.74 33/18.26 6.16 2.38 × 10–7 
P15650 acyl-CoA dehydrogenase, long-chain-specific, 
mitochondrial precursor 
14 10/41.53 72/40.47 5.78 1.59 × 10–
13 
Q9CZU6 citrate synthase, mitochondrial precursor 10 5/19.25 33/18.75 5.52 1.06 × 10–6 
P83741 serine/threonine-protein kinase WNK1 3 4/8.10 12/7.90 3.24 0.036 
P42123 l-lactate dehydrogenase B chain 12 15/23.80 32/23.20 2.26 0.0094 
O08749 dihydrolipoyl dehydrogenase, mitochondrial 
precursor 
10 37/53.68 69/52.32 1.88 0.0011 
P16951 cyclic AMP-dependent transcription factor 
ATF-2 
1 18/24.82 31/24.18 1.64 0.050 
 
Table 4. Ion and Small Molecule Channels plus Modulators Eluted by Both Rosiglitazone and Pioglitazone from the Glitazone Scaffold-Based Columna 
      scan count    
accession no. annotated protein peptides rosi/exp pio/exp norm p 
P10719 ATP synthase β chain, mitochondrial 10 34/32.4 30/31.6 0.69 
P15999 ATP synthase α chain, mitochondrial 18 70/62.8 54/61.2 0.2 
O35454 chloride channel protein 6 1 9/12.7 16/12.3 0.14 
P20059 hemopexin 3 0/4.6 9/4.4 3.6 × 10–4# 
P70600 focal adhesion kinase 2 1 6/5.6 5/5.4 0.8 
Q9QXY7 membrane transport protein XK 1 61/46.6 31/45.4 0.0024* 
Q4FZZ1 PX domain-containing protein kinase-like protein (modulator of Na,K-ATPase) 1 23/16.2 9/15.8 0.014* 
P83741 serine/threonine-protein kinase WNK1 3 4/8.1 12/7.9 0.036# 
O70247 sodium-dependent multivitamin transporter 1 4/5.6 7/5.4 0.34 
Q5QD11 trace amine-associated receptor 7b 1 0/6.6 13/6.4 1.83 × 10–5# 
Q9JIS7 voltage-dependent L-type calcium channel, α-1F subunit 3 14/10.6 7/10.4 0.14 
a∗ denotes significant p-value for an increase with rosiglitazone and # denotes significant p-value for increase with pioglitazone. 
Table 5. Heart Proteins Eluted from the Glitazone Scaffold-Based Column Using Rosiglitazone and Pioglitazone That Are Implicated in Neuronal 
Synaptic Transmission or Developmenta 
      scan count    
accession no. annotated protein peptides rosi/exp pio/exp norm p 
Q8CGZ2 afadin- and α-actinin-binding protein 1 12/11.6 11/11.4 0.88 
Q91ZU6 bullous pemphigoid antigen 1 (dystonin) 12 9/7.6 6/7.4 0.47 
Q9QZM3 cardiotrophin-like cytokine factor 1 1 25/17.7 10/17.3 0.0.012* 
O08788 dynactin-1 3 13/11.1 9/10.9 0.43 
P97924 Huntingtin-associated protein-interacting protein (kalirin) 3 27/30.4 33/29.6 0.38 
Q9EPL8 importin-7 1 15/13.2 11/12.8 0.47 
Q04859 serine/threonine-protein kinase MAK 1 16/16.2 16/15.8 0.94 
Q8VBX6 multiple PDZ domain protein 2 9/10.1 11/9.9 0.61 
P48744 norrin 1 52/26.3 0/25.7 4.05 ×10–17* 
Q04690 neurofibromin 3 12/8.1 4/7.9 0.046* 
Q9JLB5 neuronal acetylcholine receptor protein, α-10 subunit 1 7/6.1 5/5.9 0.59 
Q9WVE8 protein kinase C and casein kinase substrate in neurons protein 2 1 14/7.1 0/6.9 1.27 × 10–5* 
O88761 26S proteasome non-ATPase regulatory subunit 1 3 15/13.7 12/13.3 0.61 
Q9Z139 tyrosine-protein kinase transmembrane receptor ROR1 1 5/6.5 8/6.4 0.38 
P35710 transcription factor SOX-5 1 11/8.6 6/8.4 0.24 
Q9QUH6 Ras GTPase-activating protein SynGAP 2 62/46.1 29/44.9 7.32 × 10–4* 
a∗ denotes significant p-value for an increase with rosiglitazone, and # denotes significant p-value for increase with pioglitazone. 
Heart Off-Target Protein Binding Profile Trends for Rosiglitazone and Pioglitazone 
Elutions 
Since most of the off-target binding partners for both rosiglitazone and pioglitazone are similar, further analysis 
of the 92 protein comparison data set focused on exploring directly affected pathways or classes of proteins 
shared between rosiglitazone and pioglitazone elutions. There were 10 ion channels or channel regulators 
detected at a similar abundance for rosiglitazone and pioglitazone, including regulators of small amine, calcium, 
chloride, sodium, and electron transport (Table 4). Identified were a voltage-dependent L-type calcium channel, 
a calcium channel regulator FAK2, mitochondrial adenosine triphosphatases (ATPases), and various modulators 
of sodium and chloride transport. L-Type calcium channels have a central role in cardiac function, including 
effects on cardian arrhythmias. Only the membrane transport protein XK (p = 0.0024) and modulator of Na,K-
ATPase (p = 0.014) were significantly increased in rosiglitazone elutions and trace amine-associated receptor 7b 
(p = 1.83 × 10–5), WNK1 (p = 0.036), and hemopexin (p = 3.6 × 10–4) in pioglitazone elutions. Interestingly, 
numerous modulators of amine transport are linked to not only cardiovascular function but also 
neurotransmitter regulation and excitable synaptic transmission. 
Numerous proteins within the rosiglitazone and pioglitazone comparison were also implicated in neuronal 
function and excitatory synaptic transmission. Not including the channels mentioned above, there were 16 
proteins in the rosiglitazone and pioglitazone comparison that mediate neuronal functions (Table 5). 
Cardiotropin-like cytokine factor 1 (p = 0.012), nerofibromin (p = 0.046), and Ras GTPase-activating SynGAP (p = 
7.32 × 10–4) were significantly increased in rosiglitazone elutions, and norrin (p = 4.05 × 10–17) plus PACSN2 (p = 
1.27 × 10–5) were unique. The other 11 proteins implicated in synaptic transmission were not significantly 
different between the drugs. To determine if the ion channels, channel modulators, and synaptic transmission 
regulators were in unique networks to the heart and not a general network of proteins throughout the body, we 
compared the heart elution profiles of rosiglitazone and pioglitazone to liver off-target binding profiles (data not 
shown) generated in the same manner as with the heart (Tables 4 and 5). Proteins identified in 
Tables 4 and 5 were found to be unique or significantly increased in the heart elution data set versus the liver, 
suggesting that the drugs bind a unique set of ion/amine channels and neuronal excitatory network in the heart. 
Rosiglitazone and pioglitazone have been shown to bind purified PPARγ with high affinity in purified samples 
and have been indirectly shown to activate the PPARγ pathway;(4, 6, 7) target organs in vivo are adipose and 
liver. However, it is unclear if this direct PPARγ interaction would occur in the rat heart. In the exploration of the 
tandem MS data sets from rosiglitazone and pioglitazone heart protein elutions off of the glitazone scaffold, 
there was no PPARγ detection. To assess whether the expression was too low in the heart for detection, the 
glitazone column elution experiments were repeated by substituting fatty rat liver tissue homogenates in place 
of those generated from the heart. PPARγ was detected minimally in rosiglitazone elutions (1 peptide/4 scans) 
but not in pioglitazone elutions off the glitazone column. On the other hand, PPARδ was detected in both 
rosiglitazone (1 peptide/3 scans) and pioglitazone (1 peptide/10 scans) elutions of liver protein off the glitazone 
column. The heart, liver, and adipose samples were further examined by PPARγ immunoblotting showing low 
expression in the heart (data not shown). The low expression of PPARγ in the heart sample also fits with known 
mRNA expression profiles for the protein in various mammalian species.(28-30) Given the low expression levels 
of transcription factors, it is expected that PPARγ detection would be challenging via MS even if present in 
elutions because of the presence of the more abundant proteins and dynamic range limitations by mass 
spectrometry. Among proteins detected in rosiglitazone and pioglitazone elutions off of the glitazone column, 
there were 22 involved in fatty acid metabolism, tricarboxylic acid metabolism, glycolysis/gluconeogenesis, and 
insulin signaling pathway regulation (Supporting Information Table 1). Within these processes mitochondrial 
respiration, the citric acid (TCA) cycle and energy regulation were implicated. The salt-inducible kinase 2 (SIK2) 
protein that phosphorylates the insulin receptor substrate 1 (IRS-1) protein at Ser794 and subsequently causes 
insulin resistance(31, 32) was also found on this list of proteins and was one of only two proteins significantly 
increased in binding versus total protein (Figure 2 and Supporting Information Table 1) in both rosiglitazone and 
pioglitazone elutions. 
Discussion and Conclusions 
The two main goals of this study were first to develop a unique two-phase selection technique for assessing 
pharmaceutical off-target protein binding and, second, to compare similarities and differences between the off-
target protein binding profiles for rosiglitazone and pioglitazone, providing clues for assessing cardiotoxicity. To 
achieve these goals, proteins from rat heart homogenates were selected for interaction with a glitazone 
privileged scaffold and eluted using high salt, glitazone, rosiglitazone, or pioglitazone, followed by subsequent 
identification via LC–MS/MS analysis. By use of sophisticated computational analysis of identified 
proteins,(27) several findings emerged that provide insights into rosiglitazone and pioglitazone mechanistic 
action within the cardiovascular system, including implications for compounding drug efficacy and cardiotoxicity. 
First, most of the heart proteins identified eluted with both rosiglitazone and pioglitazone, suggesting that they 
have a similar mechanistic action and similar potential for producing cardiotoxicity. Second, of the protein 
binding partners that were common between rosiglitazone and pioglitazone elutions from the glitazone scaffold, 
only a small subset were differentially eluted with one drug versus the other (Tables 2 and 3). Third, several 
common classes of proteins were identified in rosiglitazone and pioglitazone elutions off a glitazone scaffold 
that possess the potential for an increase in drug efficacy or adverse cardiovascular events. Some examples are 
ion channels and solute transporters, lipid metabolism proteins, and mitochondrial proteins involved in meeting 
the high energy demands of the heart. It is especially significant that ion channels, such as L-type calcium 
channels, were identified, as they play a central role in maintaining proper cardiac rhythms. Lastly, PPARγ 
elution off the glitazone scaffold was not detected in elutions from cardiac tissue most likely because of low 
levels of expression,(28-30) while it was detected in elutions from liver and adipose tissue homogenates. It is 
possible that off-target protein binding partners, in addition to PPARγ, could contribute to TZD efficacy, 
especially since data on direct binding of TZDs to the receptor in complex mixtures are not well-defined. In this 
regard, several other off-target binding partners were identified that indirectly or directly could affect the 
degree of insulin sensitivity. 
Rosiglitazone and pioglitazone are thought to exert their primary therapeutic effects through binding to the 
peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue, in turn increasing sensitivity to 
insulin and producing better glycemic control.(4-6) It is clear from previous literature that TZDs can bind purified 
PPARγ(4, 6, 7) and either directly or indirectly cause activation of the PPARγ pathway signaling as measured by 
activity assays.(5, 33) The established targets of rosiglitazone and pioglitazone, PPARγ and PPARδ, were 
detected sporadically and at low scan counts in the tandem MS analysis of various elution conditions but not at 
levels that passed the stringent run count filters. This is not surprising, since PPARγ is expressed at low levels in 
the heart,(28-30) which we also verified in our homogenates by immunoblotting (data not shown). However, rat 
liver (Supporting Information Table 2) and adipose (data not shown) tissue homogenates did not exhibit high 
levels in elutions either, although they were identified as present. This low level of detection could be because 
(1) transcription factors are present at low levels, such as with PPARγ in the heart,(28-30) making detection 
particularly challenging because of dynamic range limitations from more abundant proteins in the eluent, (2) 
PPAR is not binding the column (i.e., glitazone itself is not sufficient for binding or cofactors are required), (3) 
glitazone has higher affinity for other proteins in the complex protein homogenate compared to PPARγ, or (4) 
PPARγ could be occupied with free lipid byproducts from the homogenization step preventing drug binding. Free 
LDL levels have been shown to increase in rat serum after administration of rosiglitazone,(20) which could also 
lead to increased PPARγ pathway activation. However, questions as to whether additional drug efficacy is 
achieved through receptor-independent off-target actions of TZDs remain, since it is possible that some drug 
efficacy could be attributed to binding to proteins in addition to PPARγ.(18, 34) 
Receptor-independent actions of rosiglitazone and pioglitazone have been reported in previous literature,(18, 
34) and this study has identified numerous off-target interacting proteins involved in mitochondrial function, 
lipid/fatty acid metabolism, and glycolysis/gluconeogenesis regulation (Tables 1–4 and Supporting Information 
Table 1). Previous literature has indicated that PPARγ antagonists and transcriptional/translational inhibitors do 
not abolish TZD effects,(18, 35) suggesting that there are additional effects contributing to increasing insulin 
sensitivity. A potential nonreceptor candidate protein that has potential to directly affect insulin receptor 
sensitivity, SIK2, was detected in this study for both TZDs tested (Supporting Information Table 1). SIK2 is known 
to phosphorylate IRS-1 Ser794, rendering it inactive during nutrition deprivation, causing insulin resistance.(31, 
32) A potential alternative hypothesis for increased insulin sensitivity with application of rosiglitazone and 
pioglitazone could be that SIK2 binds to the drugs and IRS-1 Ser794 phosphorylation in adipocytes is inhibited, 
thus increasing insulin sensitivity. Additional receptor-independent off-target binding partners for the TZDs 
(Tables 1–5 and Supporting Information Table 1), as indicated in this study, are involved in altering 
mitochondrial aerobic respiration, which in turn leads to changes in metabolism, energy production, and 
consequently insulin sensitivity (Figure 4).(18, 36-38) Pyruvate dehydrogenase, malate dehydrogenase, isocitrate 
dehydrogenase, acetyl-CoA dehydrogenases, and citrate synthase are all part of the citric acid cycle proximal to 
complex I in the mitochondria and were detected to be individual or complex binding partners for TZDs. 
Previous studies suggest that TZD inhibition of complex I or proximal to the complex affect mitochondrial 
respiration and cause alterations in energy states, in turn increasing insulin-sensitizing effects.(18, 36-
38) Additionally, dehydrogenase enzymes have been shown to exhibit direct involvement in adipogenesis.(19) 
While there were slight differences in the off-target binding profiles between rosiglitazone and pioglitazone, 
there were many more similarities in individual protein and pathway comparisons, suggesting that the drugs 
may operate through similar off-target mechanisms in terms of both efficacy and potential toxicity. Resulting 
off-target binding profiles of both rosiglitazone and pioglitazone show that the drugs bind to mitochondrial 
respiratory chain proteins (Tables 1–4), as well as a large number of ion channels and solute transporters 
(Table 4) previously implicated in abnormal cardiovascular functions. Energy deprivation produced from 
inhibition of mitochondrial respiration has the potential to increase insulin sensitivity(18, 37) but could also lead 
to a lack in fulfilling the high energy demands of cardiac tissue (Figure 4). Not only were there TCA cycle proteins 
bound to both pioglitazone and rosiglitazone, ATP synthase was also bound, which is crucial for utilizing the 
proton gradient from mitochondrial respiration to produce ATP energy for tissues. TZDs have been shown to 
cause mitochondrial dysfunction and decrease mitochondrial ATP production.(18, 37, 38) Deficiencies in 
mitochondrial ATP synthase can lead to hypertrophic cardiomyopathy.(39, 40) Additionally, pioglitazone bound 
to phosphoglycerate kinase 1, triosphosphate isomerase, and creatine kinase at significantly increased amounts 
compared with rosiglitazone; all are involved in providing energy for high energy demanding tissues. 
TZD inhibition in the mitochondrial machinery can also lead to an increase in reactive oxygen species (ROS) 
through complex I inhibition.(41) TZD-induced depolarization of the mitochondria in astroglioma cells has been 
shown to increase ROS, which interacts with nitric oxide to form a cytoxic peroxynitrate.(41) Both rosiglitazone 
and pioglitazone bound numerous proteins involved in clearance of ROS. SODC and glutathione (GSH) levels 
have previously been shown to decrease, while catalase increased, in the serum of Wistar rats after application 
of rosiglitazone or pioglitazone.(20) Besides SODC and catalase, bound to both drugs was the selenocysteine 
insertion sequence binding protein 2 (SEPB2) (Table 3), which adds the essential trace element selenium to the 
reactive site of GSH peroxidase (GPx) and is required for its function. Mutations in SEPB2 exhibit a similar 
phenotype to GPx mutants and lead to an increase in ROS production, which coincidently leads to an increase in 
insulin sensitivity.(42) While SOD did not appear functionally affected in activity assays following treatment with 
both drugs (data not shown), the potential buildup of ROS in relation to alterations in any of these key points of 
regulation within the ROS pathway could lead to cardiotoxicity, possibly through an oxidase-independent 
mechanism.(41) 
In addition to channels like ATP synthase, numerous ion channels or amine transporters were bound to the TZDs 
and dysfunction in regulation could affect frequency and force of heart tissue contractions resulting in 
arrhythmia, heart attack, or even peripheral edema and congestive heart failure. Proteins detected as “top hits” 
for rosiglitazone and pioglitazone elutions included the voltage-dependent L-type calcium channel (CAC1F), 
chloride channel protein 6 (CLCN-6), neutral amino acid transporters, and membrane transport protein XK (XK). 
Disruption of the L-type calcium channel could be beneficial but certainly affects cardiac rhythym and under 
persistent alterations in activity could be a source of cardiotoxicity. Importantly, there have been reports that 
TZDs can directly interact with and affect L-type calcium channels,(24-26, 43-45) thereby validating our findings 
that suggest drug binding to CAC1F. Numerous other sodium, potassium, chloride, and amine transporters 
detected in this study have also been shown to exhibit regulation of action potential and membrane polarization 
by various TZDs.(21-23, 25, 46-50) Distinct excitatory synaptic transduction regulating proteins were also 
detected and could potentially have similar adverse effects on the heart and cardiovascular system (Table 5) but 
via the sympathetic system. 
While previous literature clearly suggests that rosiglitazone increases the risk of adverse cardiac-related 
events,(10, 11) our data would suggest that pioglitazone is very similar in terms of the rat heart binding profiles. 
These profiles identify potential direct sources contributing to both efficacy and cardiotoxicity via perturbations 
in mitochondrial function, cardiac ion channels (for example, L-type calcium channels), and disruption of the 
cardiac sympathetic signaling. While rosiglitazone and pioglitazone off-target protein binding profiles are very 
similar in composition, there is the chance for variance in effects based on affinity for the particular protein 
leading to slight differences in efficacy or cytotoxicity.(49, 51-53) Additionally, it is recognized that long-term 
dosing of an animal model with rosiglitazone or pioglitazone may lead to increased levels of additional off-target 
binding partners and that indirect effects could contribute to efficacy and cardiotoxicity (Figure 4). One must 
also keep in mind that patients taking these drugs are also the severe type II diabetic patients for whom other 
forms of regulation are not therapeutically effective and their cardiovascular system is already severely impaired 
making them high risk, which could also be a contributing factor. There is also literature that suggests that 
adverse events could be dependent on age and increasing cardiotoxicity in elderly patients.(11, 15) 
 
Figure 4. Model summarizing rosiglitazone and pioglitazone (1) receptor-independent (off-target) interactions 
detected in this study and the (2) receptor-dependent interaction with PPARγ leading to increased insulin 
sensitivity. Off-target interactions that potentially increase cardiotoxicity include effects on ion channels leading 
to cardiac arrhythmias, altered membrane potential, and congestive heart failure. Additionally, mitochondrial 
dysfunction would affect energy regulation in the heart, not only leading to cardiotoxicity but also indirectly 
contributing to efficacy of the drugs. 
The techniques presented herein, which provide a comparison of binding profiles as chemical structures of drugs 
are varied, could also be used to make additional improvements to existing drugs or to find existing drugs with 
similar elution profiles. Once proteins associated with potential for adverse effects are identified, the core 
scaffold can be systematically modified to tune the binding profile in such a way as to avoid binding to undesired 
proteins, as described previously.(17) The latter application suggests utility in repurposing drugs to identify 
drugs with desirable off-target binding profiles, if one elutes from a column containing a core from one drug, 
using a second drug that is thought to operate by a different mechanism but actually may bind similar proteins. 
Experimental approaches such as this are the subject of ongoing studies in our laboratories and provide 
invaluable information to decipher both beneficial and cytotoxic interactions of drugs. 
Experimental Methods 
Coupling of Glitazone to the Epoxy Resin 
Epoxide resin (1.5 g) was incubated in phosphate buffer solution (Na2HPO4 and KH2PO4) at pH 10 for 3 h. Then 
0.8 g of K2CO3 and 1.9 g of glitazone were added, followed by gentle aggitation for 3 days at room 
temperature. p-Cresol, potassium carbonate, potassium phosphate (monobasic), sodium phosphate (dibasic), 
and an epoxide functionalized resin (∼2 mmol/g) were from Alfa Aesar, and 5-(4-hydroxybenzyl)-1,3-
thiazolidine-2,4-dione (glitazone, ≥97% purity as determined by HPLC) was from Accela ChemBio Inc. IR spectra 
were collected on a Nicolet 560 FT-IR spectrometer, in a KBr pellet, to confirm coupling. In the same manner, a 
control column was prepared by coupling with 1.6 g of p-cresol (Alfa Aesar) in place of glitazone. 
Preparation of Rat Heart and Liver Homogenates 
Sprague–Dawley rats of 8–10 weeks of age on a 4% NaCl diet were sacrificed using 0.3 mL of Beuthenasia. 
Hearts and livers were excised and quartered into 2 mL microcentrifuge tubes followed by liquid nitrogen snap 
freezing. Then 5 mm stainless steel beads (Qiagen, catalog no. 69989) were added to each tube for bead 
homogenization along with 1 mL of low salt 1× TBS, pH 7.8. A TissueLyser II was used at 20 Hz frequency for 90 s 
three times and 30 Hz for 120 s two times to generate crude homogenates for heart and liver samples. Crude 
homogenates were centrifuged at 3500g (4600 rpm) for 15 min at 4 °C for removal of high molecular weight 
debris. Supernatants were transferred to 2 mL Beckman centrifuge tubes and balanced and underwent 
ultracentrifugation for 30 min at 100000g (55 000 rpm) at 4 °C. Supernatants were transferred to a fresh tube, 
and microsomal pellets were resuspended in 0.5–1.0 mL of low salt 1× TBS, pH 7.8, depending on the pellet size. 
MicroBCA assay (BioRAD) was then performed on the soluble and microsomal protein fractions, while the 
remaining protein mixtures were snap frozen and stored at −80 °C for future use. 
Eluting Rat Heart Protein Using Glitazone 
Both the glitazone and control columns were equilibrated in buffer A (low salt TBS: 25 mM Tris-HCl, 50 mM 
NaCl, pH 7.8). Then 0.5 mg of protein sample (either soluble or membrane fraction) was loaded onto the 
columns and incubated for 15 min. Then both columns were washed with buffer A (10–15 bed volumes), and 
flow-through was saved. Columns were eluted using buffer B (2 mM glitazone in buffer A), and fractions were 
collected. Columns were flushed using high salt TBS buffer (1 M NaCl, 10 mM Tris, pH 7.8) and then re-
equilibrated with 20 bed volumes of buffer A. 
Eluting Rat Liver Protein Using Rosiglitazone and Pioglitazone 
The glitazone column was equilibrated in low salt TBS (25 mM Tris-HCl, 50 mM NaCl, pH 7.8). Then 0.5 mg of 
protein sample (either soluble or membrane fraction) was loaded onto the column and incubated for 15 min. 
Then the column was washed with buffer A (10–15 bed volumes), and flow through was saved. Column was 
eluted with buffer B (50 or 500 μM rosiglitazone or pioglitazone in buffer A), and fractions were collected. 
Columns were flushed using high salt TBS (1 M NaCl, 10 mM Tris), pH 6.8, and re-equilibrated with buffer A. 5-
[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride (pioglitazone or Actos) 
was from Sigma-Aldrich and 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione 
(rosiglitazone or Avandia) was from Cayman Chemical Company. Both rosiglitazone and pioglitazone were ≥98% 
pure as determined by HPLC. 
Preparation of Samples for Mass Spectral Analysis 
Buffer exchange into 50 mM ammonium bicarbonate was performed using Amicon Ultra-15 Ultracel centrifugal 
filters with a 3000 Da molecular weight cutoff (Millipore, Billerica, MA) using four 20 min cycles at 3500g. 
Samples were dried using a vacuum centrifuge and resuspended in 100 μL of 50 mM ammonium bicarbonate. 
Protein samples were then reduced with 10 mM dithiothreitol at 56 °C for 30 min, cooled to room temperature, 
alkylated with 20 mM iodoacetamide for 30 min in the dark, and digested using 0.5 μg of sequencing grade 
trypsin (Promega) overnight (∼16 h) at 37 °C. Peptide mixtures were acidified (∼pH 4), and Varian Omix C18 
desalting tips (Agilent Technologies, Santa Clara, CA) were used to clean and elute peptides. Desalted peptides 
were dried using a vacuum centrifuge and resuspended in 98% HPLC water/2% ACN/0.1% formic acid. 
Liquid Chromatography and Mass Spectrometry 
Tryptic peptide mixtures (1.9 μL) were injected via a NanoAccuity UPLC system (Waters, Milford, MA) and 
passed over an in-house packed C18 resin (Phenomenex, Torrance, CA) column (10 cm long, 50 μm inner 
diameter). A gradual gradient from 98% HPLC water/2% ACN/0.1% formic acid to 98% ACN/2% HPLC water/0.1% 
formic acid was applied to peptide mixtures. As peptides eluted, they were analyzed using an Orbitrap Velos 
mass spectrometer (Thermo Scientific, Waltham, MA). Initial parent ion scans (MS1) were performed in the 
FTMS portion with 106 ions collected over a maximum accumulation time of 500 ms and a resolution of 30 000 
at full width of a spectral peak at half-maximum peak height (fwhm at 400 m/z). The 10 most abundant ions 
were selected for collision induced dissociation fragmentation (MS/MS) in the LTQ ion trap portion of the 
instrument with an ion intensity threshold of 500 and a normalized collision energy of 35%. Ten-thousand ions 
were collected from fragmentation spectra over a maximum accumulation time of 25 ms. Dynamic exclusion 
was used, excluding any given mass observed more than once in a 30 s time frame for 180 s from selection for 
fragmentation. 
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Abbreviation Used 
LTQ linear trap quadrupole 
TZD thiazolidinedione 
SOD superoxide dismutase 
SIK2 salt-inducible kinase 2 
IRS-1 insulin receptor substrate 1 
CLCN-6 chloride channel protein 6 
CAC1F voltage-dependent L-type calcium channel 
SEPB2 selenocysteine insertion sequence binding protein 2 
GSH glutathione 
GPx glutathione peroxidase 
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